A Comparison of Three Regimens of Acute Pain Management: Methoxyflurane; Intranasal Fentanyl; Intravenous Morphine

Summary

The study rationale is to provide evidence for early, safe and effective pain management in the ambulance service with non-invasive and fast acting analgesics. Low-dose methoxyflurane and intranasal fentanyl are non-invasive medications that are well-suited for use by ambulance personnel under difficult pre-hospital settings. This is a randomized, controlled, open label, three-arm, non-inferiority, phase 3 drug trial performed in the ambulance service. The randomization will be 1:1:1 to the three treatment groups.

Patients 18 years or older with acute pain with Numeric Rating Scale (NRS) ≥4 with normal physiology and capable of giving informed consent will be included null hypothesis (H0) (tested in hierarchic order a-b-c):

1. Methoxyflurane regimen is inferior to intranasal fentanyl regimen or
2. Methoxyflurane regimen is inferior to IV morphine regimen or
3. Intranasal fentanyl regimen is inferior to IV morphine regimen for treating moderate to severe pain, measured by reduction in Numeric Rating Scale (NRS) 10 minutes after administration.

The study duration for each participant will be from ambulance scene arrival to patient handover in emergency department.

Number of participants: Patient enrolment until successful inclusion of 270 per protocol patients.

Primary endpoint is change in NRS from before administration (t0) to 10 minutes after start of administration (t10).

The study intervention is one of the three IMPs:

* Methoxyflurane: 3 ml inhalation, can be repeated once to a total dose of 6 ml.
* Fentanyl intranasal spray: 100 µg IntraNasal, (patients \>70 years 50 µg), can be repeated to maximum total dose 500 µg IN.
* Morphine hydrochloride intravenous: 0.1 mg/kg IV (patients \>70 years or fragile 0.05 mg/kg IV), can be repeated to a maximum total dose 0.5 mg/kg IV.

Rescue analgesia is all analgesics other than the allocated IMP. If rescue medication is administered before the assessment of primary endpoint at 10 minutes, the patient will not be part of the per-protocol analysis.

The hypothesis will be tested and the primary endpoint will be evaluated by the 95% confidence limits (95% CI), and a conclusion of non-inferiority will be made if the 95% CI of the estimated treatment difference fully lie within the inferiority margin. Non-inferiority is determined on the basis of a 1-sided equivalence t test on the per protocol population and confirmed, for sensitivity reasons, on the modified intention to treat population.

Conditions

• Acute Pain
• Ambulances

Interventions

DRUG

Methoxyflurane

Inhalation of Methoxyflurane

DRUG

Fentanyl

Intranasal Fentanyl

DRUG

Morphine hydrochloride

Intravenous Morphine

Sponsors & Collaborators

• Sykehuset Innlandet HF

  collaborator OTHER

• Norwegian Air Ambulance Foundation

  collaborator OTHER

• University of Oslo

  collaborator OTHER

• Oslo University Hospital

  lead OTHER

Principal Investigators

• Fridtjof Heyerdahl, MD PhD · Senior Consultant

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-11-12

Primary Completion

2023-04-22

Completion

2023-04-22

Countries

• Norway

Study Locations